Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

NCT00093639 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Leukemia

Interventions

DRUG: everolimus
DRUG: imatinib mesylate

Sponsor

Novartis Pharmaceuticals